Heparine CoF II

Heparine CoF II

Heparin cofactor II (HCII; EC 3.4.21.xx) is a serine protease inhibitor (serpin) that inactivates thrombin rapidly in the presence of certain glycosaminoglycans (GAGs; dermatan sulfate, heparan sulfate, or heparin), but does not inhibit other proteases involved in coagulation or fibrinolysis. Heparin cofactor II has several biochemical properties that distinguish it from other serpins: it specifically inhibits thrombin, and the mechanism of inhibition involves binding of an acidic domain in HCII to thrombin exosite I. The rate of inhibition increases dramatically (more than 1000-fold) in the presence of heparin, heparan sulfate, or dermatan sulfate. HCII has been proposed to regulate coagulation or to participate in processes such as inflammation, atherosclerosis, and wound repair.

Read More
sort-descending
  • Odiparcil
    1536
    The price depends on the options chosen on the product page

    From $198.00

1 Item

More About Heparine CoF II

Heparin cofactor II (HCII; EC 3.4.21.xx) is a serine protease inhibitor (serpin) that inactivates thrombin rapidly in the presence of certain glycosaminoglycans (GAGs; dermatan sulfate, heparan sulfate, or heparin), but does not inhibit other proteases involved in coagulation or fibrinolysis. Heparin cofactor II has several biochemical properties that distinguish it from other serpins: it specifically inhibits thrombin, and the mechanism of inhibition involves binding of an acidic domain in HCII to thrombin exosite I. The rate of inhibition increases dramatically (more than 1000-fold) in the presence of heparin, heparan sulfate, or dermatan sulfate. HCII has been proposed to regulate coagulation or to participate in processes such as inflammation, atherosclerosis, and wound repair[1],[2].


[1] D.M. Tollefsen et al. Heparin cofactor II modulates the response to vascular injury. Arterioscler. Thromb. Vasc. Biol. 2007, 27, 454-460.
[2] L. He et al. Heparin cofactor II inhibits arterial thrombosis after endothelial injury. J. Clin. Invest. 2002, 109, 213-219.

Loading...